Professor Luke Selth

Lab webpage: Prostate Cancer Research Group

Google Scholar: https://scholar.google.com.au/citations?user=IfXWSaQAAAAJ&hl=en

ORCID: https://orcid.org/0000-0002-4686-1418

Professor Luke Selth is a Cancer Council SA Beat Cancer Principal Research Fellow in the Flinders Health and Medical Research Institute (FHMRI) at Flinders University, where he leads the Prostate Cancer Research Group.

Selth has established an internationally-recognised research program focused on understanding and targeting androgen receptor signalling in prostate cancer, investigating cancer cell plasticity and how it leads to therapy resistance, and testing the efficacy of novel drugs for prostate cancer.

Selth did a Biotechnology degree at Flinders University, a PhD at University of Adelaide and then post-doctoral studies at Cancer Research UK’s London Research Institute. As a recipient of a prestigious European Molecular Biology Organization long-term fellowship, Selth studied epigenetic mechanisms underlying transcriptional deregulation in cancer and developed expertise in contemporary molecular, biochemical and omic techniques. Since returning to Australia, Selth’s research has been focussed on prostate cancer, an extremely common disease and a major cause of cancer-related death in men.

Selth is a member of the Freemasons Centre for Male Health and Wellbeing and the Scientific Advisory Committee for the South Australian Genomics Centre. He has received Young Investigator Awards from the Prostate Cancer Foundation of Australia and the Prostate Cancer Foundation, as well as funding from NHMRC, Cancer Australia, Cancer Council SA, Cancer Council NSW, the Flinders Foundation, Movember and The Hospital Research Foundation. He is an Editorial Board member of Endocrine-Related Cancer, the flagship cancer journal for the Society of Endocrinology, and Cancer Research Communications, the open access journal of the American Association for Cancer Research. His team’s research is regularly published in prominent journals including recent papers in Cancer Research, European Urology, Science Translational Medicine, Nature Cell Biology, Nature Medicine, EMBO Journal, Oncogene, and Nucleic Acids Research.